Initial Management of Uncontrolled Hypertension

Initial Assessment and Medication Selection

The European Society of Cardiology recommends that patients with uncontrolled hypertension (BP ≥140/90 mmHg) should be treated with both lifestyle advice and BP-lowering medication 1
For patients with BP between 140/90 mmHg and 159/99 mmHg, the American Diabetes Association suggests that treatment may begin with a single drug, but combination therapy is preferred 2
The European Society of Cardiology strongly recommends initial treatment with two antihypertensive medications for patients with BP ≥160/100 mmHg 2
Single-pill combinations improve medication adherence and should be preferred over separate pills, according to the European Heart Journal 3

First-line medications include four major drug classes, including ACE inhibitors, Angiotensin receptor blockers (ARBs), Dihydropyridine calcium channel blockers, and Thiazide or thiazide-like diuretics, as recommended by the European Heart Journal 3

Effective and well-tolerated two-drug combinations include Thiazide diuretic + ACE inhibitor, Thiazide diuretic + ARB, Calcium antagonist + ACE inhibitor, and Calcium antagonist + ARB, as suggested by the European Heart Journal 3

The European Society of Cardiology recommends that in Black patients, initial treatment should include a diuretic or calcium channel blocker, either alone or in combination with a RAS blocker 1
For patients with diabetes and albuminuria, the American Diabetes Association recommends an ACE inhibitor or ARB as first-line therapy 2
The European Society of Cardiology suggests that for patients with heart failure with reduced ejection fraction, treatment should include an ACE inhibitor (or ARB), beta-blocker, and diuretic/MRA if required 1
For patients with chronic kidney disease, the European Society of Cardiology recommends a target systolic BP of 120-139 mmHg, with RAS blockers recommended in the presence of albuminuria 1

The American Heart Association recommends monthly visits until blood pressure target is achieved 4
For patients treated with ACE inhibitors, ARBs, or diuretics, the American Diabetes Association suggests that serum creatinine/eGFR and potassium levels should be monitored at least annually 2
The American Heart Association recommends home BP monitoring or ambulatory BP monitoring to confirm diagnosis and monitor treatment effectiveness 4

The European Society of Cardiology recommends reinforcement of lifestyle measures, especially sodium restriction, for patients with resistant hypertension 1
The European Society of Cardiology suggests addition of spironolactone at low dose to existing treatment for patients with resistant hypertension 1

The American Heart Association recommends sodium restriction to <1500 mg/day or reduction of at least 1000 mg/day 5
The American Heart Association suggests increased potassium intake (3500-5000 mg/day) 5
The American Heart Association recommends weight loss if overweight/obese 5
The American Heart Association suggests physical activity (aerobic or dynamic resistance 90-150 min/week) 5
The American Heart Association recommends moderation of alcohol intake (≤2 drinks per day in men, ≤1 per day in women) 5
The American Heart Association suggests a DASH-like diet rich in fruits, vegetables, whole grains, and low-fat dairy products 5

The European Society of Cardiology recommends that all patients must be stratified by total cardiovascular risk, not just BP level alone, to determine treatment intensity and urgency 6, 7
Patients with high or very high cardiovascular risk, such as those with diabetes, established CVD, chronic kidney disease, or multiple risk factors, should initiate combination therapy immediately even at BP levels of 140-159/90-99 mmHg 8
The European Society of Cardiology categorizes risk into low, moderate, high, and very high added risk, with corresponding treatment approaches 7

For patients with BP ≥160/100 mmHg, the European Society of Cardiology recommends initiating treatment with two antihypertensive medications from the start, preferably as a single-pill combination 9
The American Diabetes Association recommends using ACE inhibitors or ARBs as mandatory first-line therapy in patients with diabetes and albuminuria 9
The European Society of Cardiology recommends avoiding the thiazide + beta-blocker combination in patients with metabolic syndrome or high diabetes risk due to dysmetabolic effects 10, 8

The American Heart Association recommends an intensive target BP of <130/80 mmHg for patients with established CVD, diabetes, chronic kidney disease, or high cardiovascular risk 11
The European Society of Cardiology recommends monitoring serum creatinine/eGFR and potassium at least annually when using ACE inhibitors, ARBs, or diuretics 9
The American College of Emergency Physicians recommends assessing for white coat hypertension and avoiding rapid BP lowering in asymptomatic patients in the emergency department 12

The European Society of Cardiology recommends avoiding sequential monotherapy as the default approach, as it is laborious, frustrating, and delays BP control in high-risk patients 13, 8
The European Society of Cardiology recommends addressing medication adherence issues proactively, as poor compliance is the most common cause of resistant hypertension 14, 9

The European Society of Cardiology recommends adding spironolactone at low dose as a fourth agent in patients with resistant hypertension 14, 9
The European Society of Cardiology recommends excluding secondary causes of hypertension, such as obstructive sleep apnea, renal artery stenosis, primary aldosteronism, and medication non-adherence 14